Cantor Fitzgerald Reaffirms Overweight Rating for Mesoblast (NASDAQ:MESO)

Mesoblast (NASDAQ:MESO)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a report issued on Thursday, Benzinga reports.

Several other equities analysts have also recently weighed in on MESO. StockNews.com upgraded Mesoblast from a “sell” rating to a “hold” rating in a report on Tuesday. Jefferies Financial Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating in a report on Thursday. Finally, Piper Sandler upgraded shares of Mesoblast from a “neutral” rating to an “overweight” rating and upped their price target for the company from $4.00 to $11.00 in a report on Tuesday, July 23rd.

Mesoblast Stock Performance

MESO stock traded down $0.02 during midday trading on Thursday, hitting $6.35. 46,516 shares of the company’s stock were exchanged, compared to its average volume of 958,396. Mesoblast has a one year low of $1.61 and a one year high of $8.66. The company has a market cap of $725.03 million, a PE ratio of -5.71 and a beta of 3.48. The stock’s fifty day moving average price is $6.86 and its 200-day moving average price is $5.78.

Institutional Investors Weigh In On Mesoblast

Several institutional investors have recently bought and sold shares of MESO. GAMMA Investing LLC grew its stake in shares of Mesoblast by 50.1% during the 2nd quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after acquiring an additional 1,663 shares in the last quarter. Perkins Coie Trust Co bought a new stake in shares of Mesoblast in the second quarter worth $68,000. Pine Valley Investments Ltd Liability Co acquired a new position in Mesoblast during the second quarter worth $80,000. Rathbones Group PLC bought a new position in Mesoblast in the second quarter valued at $95,000. Finally, Chapin Davis Inc. grew its position in Mesoblast by 50.0% in the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.